Search results for " Breast Cancer"
showing 10 items of 427 documents
The HERBA trial: a retrospective study on patients (pts) with HER2-positive (HER2+ve) breast cancer (BC) and brain metastases (BMs)
2017
BIOLOGICAL EFFECTS OF JAHA, A NEW HISTONE DEACETYLASE INHIBITOR, ON CANCER CELLS FROM HUMAN BREAST EPITHELIUM
The histone deacetylase inhibitors (HDACis) are a class of chemically heterogeneous anticancer agents of which suberoylanilide hydroxamic acid (SAHA) is a prototypical member. SAHA derivatives may be obtained by the three-dimensional manipulation of the SAHA aryl cap, such as the incorporation of a ferrocene unit like that present in Jay Amin hydroxamic acid (JAHA) and homo-JAHA (Spencer et al., 2011). These metal-based SAHA analogues have been tested for their cytotoxic activity toward triple-negative MDA-MB231 breast cancer cells. The results obtained indicate that of the two compounds tested, only JAHA was prominently active on breast cancer cells with an IC50 of 8.45 μM at 72 h of treat…
Fulvestrant and trastuzumab in patients with luminal HER2-positive advanced breast cancer (ABC): an Italian real-world experience (HERMIONE 9)
2021
Purpose: The most appropriate therapy for HR + /HER2-positive (HER2 +) advanced breast cancer (ABC) is a matter of debate. Co-targeting of both receptors represents an attractive strategy to overcome the cross-talk between them. Methods: The HERMIONE 9 is an observational retrospective multicentric study which aimed to describe the clinical outcome of patients with HR + /HER2 + ABC who received the combination of Fulvestrant (F) and Trastuzumab (T) as part of their routine treatment at 10 Italian Institutions. Results: Eighty-seven patients were included. Median age was 63 (range, 35–87) years. The median number of previous treatments was 3 (range, 0–10) and F and T were administered as ≥ 3…
DIFFERENTIAL INFLUENCE OF HYPOXIA ON GENE EXPRESSION OF TUMORAL AND NON TUMORAL MAMMARY CELLS
2015
Cancer metastasis is the result of a series of deregulated biological phenomena, including alterations of cell-cell and cell-matrix interactions and of other microenvironmental conditions such as the oxygen tissue supply. Hypoxia is a well-known driver of aggressive cancer phenotypes, indeed tumors with poor prognosis have higher proportions of anoxic and hypoxic areas1. The consequences of tumour hypoxia can be local or even systemic towards distant organs, and it can evoke diversified responses: whereas low oxygen concentration in tissue environments. (pO2 <7 mmHg) exerts anti-proliferative effects and promotes differentiation, apoptosis and/or necrosis on normal cells, the tumoral cells …
Multiple effects induced by herceptin® on 8701-BC breast cancer cells
2008
Herceptin, an anti-neoplastic humanized monoclonal antibody (Herceptin®, Roche, CH), has been shown to be active against breast cancer cells over-expressing HER-2 receptor. HER-2 is a cell membrane protein that belongs to the epidermal growth factor receptors family and that results over-expressed in the 25-30% of breast cancer patients. The over-expression of HER-2 is considered a predictive and prognostic marker for breast cancer malignancy and invasiveness. On these bases, we aimed to analyze the effects caused by Herceptin treatment on 8701-BC breast cancer cells (Minafra et al., 1989). Firstly we evaluated the effects of Herceptin on the growth rate of 8701-BC cells. To this purpose, p…
Herceptin Resistance and Malignant Potential of Cancer Cells.
2009
Herceptin-resistance in breast cancer cells: a proteomic study.
2009
HER-2 is a cell membrane protein that belongs to the ErbB family of receptor tyrosine kinases (HER-1, HER-2, HER-3, HER-4). The over-expression of HER-2, which results in the 25-30% of breast cancer patients, is considered a predictive and prognostic marker for breast cancer malignancy and invasiveness and makes HER-2 an excellent therapeutic target. In the last years new therapeutic strategies have been improved in order to better deal tumor diseases an to minimize collateral effects due to classic chemotherapy in patients. In this way, a new approach was the somministration of humanized antibodies directed against tumor-associated molecular targets. Among these ones Herceptin, an anti-neo…
Increased expression of leptin and the leptin receptor as a marker of breast cancer progression: possible role of obesity-related stimuli.
2006
Abstract Purpose: Recent in vitro studies suggested that the autocrine leptin loop might contribute to breast cancer development by enhancing cell growth and survival. To evaluate whether the leptin system could become a target in breast cancer therapy, we examined the expression of leptin and its receptor (ObR) in primary and metastatic breast cancer and noncancer mammary epithelium. We also studied whether the expression of leptin/ObR in breast cancer can be induced by obesity-related stimuli, such as elevated levels of insulin, insulin-like growth factor-I (IGF-I), estradiol, or hypoxic conditions. Experimental Design: The expression of leptin and ObR was examined by immunohistochemistry…